Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 5/20 | 0.51 |
| ▸ | SLC40A1 | Q9NP59 | 5/20 | 0.51 |
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.48 |
| ▸ | NMT1 | P30419 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 2/20 | 0.44 |
| ▸ | OXTR | P30559 | 1/20 | 0.43 |
| ▸ | EDNRB | P24530 | 1/20 | 0.43 |
| ▸ | EDNRA | P25101 | 1/20 | 0.43 |
| ▸ | ALPL | P05186 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16926599 | 0.90 | PIK3C3 (0.57) | CCR2SLC40A1PIK3C3NMT1KIT | |
| SCHEMBL16913898 | 0.88 | PIK3C3 (0.56) | CCR2PIK3C3NMT1 | |
| SCHEMBL20102458 | 0.81 | CCR4 (0.50) | SLC40A1PIK3C3EDNRBEDNRA | |
| SCHEMBL16913865 | 0.81 | PIK3C3 (0.58) | CCR2PIK3C3 | |
| SCHEMBL17001151 | 0.81 | CCR2 (0.57) | CCR2SLC40A1PIK3C3NMT1KIT | |
| SCHEMBL16996875 | 0.75 | EDNRB (0.53) | PIK3C3EDNRBEDNRAALPL | |
| SCHEMBL790913 | 0.74 | PIK3C3 (0.59) | PIK3C3 | |
| SCHEMBL20099852 | 0.72 | PIK3C3 (0.39) | CCR2SLC40A1PIK3C3KITALPL | |
| SCHEMBL16926703 | 0.70 | CCR2 (0.50) | CCR2SLC40A1PIK3C3KITOXTR | |
| SCHEMBL17001158 | 0.68 | PIK3C3 (0.59) | CCR2PIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10538533-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-01-21 | — | — | US | disclosed |
| US-20180118762-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118762-A1 | HETEROARYLS AND USES THEREOF | VPS35, VPS4B, VPS26B | CCR2 1505/4885SLC40A1 2151/4885PIK3C3 1186/4885 |
| US-10538533-B2 | Heteroaryls and uses thereof | VPS35, VPS4B, VPS26B | CCR2 1505/4885SLC40A1 2151/4885PIK3C3 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.